Phase 3 LIBRETTO-531 trial : Lilly’s Retevmo meets primary endpoint of PFS

By on    General business news  

Phase 3 LIBRETTO-531 trial : Lilly’s Retevmo meets primary endpoint of PFS

Eli Lilly and Company (NYSE: LLY) unveiled exceptional results from their LIBRETTO-531 study of Retevmo (selpercatinib), setting a new standard in the treatment of advanced RET-mutant medullary thyroid cancer (MTC). The Phase 3 clinical trial distinctly highlights Retevmo’s superiority over existing first-line treatments, namely multikinase inhibitors cabozantinib and vandetanib. Retevmo demonstrated a statistically significant and […]

LIBRETTO-431 study: Lilly’s Retevmo emerges as potential first-line treatment for RET fusion-positive NSCLC

By on    Pharma Industry News  

LIBRETTO-431 study: Lilly’s Retevmo emerges as potential first-line treatment for RET fusion-positive NSCLC

Eli Lilly and Company (NYSE: LLY) has unveiled top-line results from the LIBRETTO-431 study, which focused on the assessment of Retevmo against platinum-based chemotherapy plus pemetrexed in patients diagnosed with RET fusion-positive advanced non-small cell lung cancer (NSCLC). The findings showcased a notable improvement in progression-free survival (PFS), a primary objective of the study. Study […]